Sudarshan Pharma Industries Limited has announced a board meeting scheduled for January 28, 2026, to review and approve the company's quarterly financial performance. The pharmaceutical company informed BSE Limited about this development through an official communication dated January 22, 2026.

Board Meeting Details

The Board of Directors will convene on Wednesday, January 28, 2026, with the primary agenda being the consideration and approval of unaudited financial results for the quarter ended December 31, 2025. The meeting will cover both standalone and consolidated financial statements for the third quarter of FY26.

Regulatory Compliance

The announcement has been made pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates listed companies to inform stock exchanges about board meetings where financial results will be considered, ensuring transparency and timely disclosure to investors and stakeholders.

Trading Window Restrictions

Sudarshan Pharma Industries has notified that the company's trading window will continue to remain closed until 48 hours after the declaration of the financial results for the quarter ended December 31, 2025. This measure is implemented to prevent insider trading and ensure fair market practices during the period when price-sensitive information is being processed and disclosed.

Company Information

Sudarshan Pharma Industries Limited operates from its head office located at 301, Aura Biplax, Premium Retail Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092. The company is listed on BSE with scrip code 543828 and trades under the symbol SUDARSHAN. The official communication was signed by Nirav Shah, Company Secretary and Compliance Officer, emphasizing the company's commitment to regulatory compliance and transparent corporate governance practices.

Sudarshan Pharma Industries Limited has successfully concluded its postal ballot process for the appointment of Dr. Vijay Ojha as Non-Executive Independent Director. The company announced the voting results on January 14, 2026, showing unanimous approval from participating shareholders.

Postal Ballot Results

The resolution for Dr. Vijay Ojha's appointment received overwhelming support from shareholders across all categories. The voting process, conducted entirely through electronic means via NSDL, concluded on January 13, 2026.

Director Appointment Details

Dr. Vijay Ojha was initially appointed as Additional Director (Non-Executive Independent) on October 18, 2025, based on the recommendation of the Nomination Remuneration Committee. The postal ballot sought formal shareholder approval for his appointment as Independent Director for a five-year term.

Professional Background and Committee Roles

Dr. Vijay Ojha brings over 30 years of industrial experience in the pharmaceutical sector, specifically in API and formulation development, scale-up commercialization. He holds a Doctorate of Philosophy (PhD) from Central Drug Research Institute, Lucknow. His professional experience includes associations with prominent pharmaceutical companies such as Lupin Limited, Sun Pharmaceuticals Limited, IPCA Laboratories Limited, and Flavine Inc., USA.

Upon appointment, Dr. Ojha will serve as a member of key board committees including the Stakeholders Relationship Committee and Nomination Remuneration Committee.

Voting Process Timeline

The company engaged National Securities Depository Limited (NSDL) to provide remote e-voting facility to shareholders. Mr. Vishal Manseta (Membership No.: 25183, COP No.: 8981), Company Secretary in Practice, served as Scrutinizer for conducting the postal ballot process.

The successful completion of the postal ballot process strengthens Sudarshan Pharma Industries' board composition with Dr. Ojha's extensive pharmaceutical industry expertise and compliance with corporate governance requirements.